Switching From or To Vyvanse: Protocols, Dose Conversions, and Clinical Evidence

The FDA approved Vyvanse (lisdexamfetamine dimesylate) as a prodrug stimulant to treat ADHD in children 6 years and older, as well as moderate-to-severe binge eating disorder in adults. Although Vyvanse is often mentioned together with other ADHD medications like Adderall, Concerta, Strattera, and Intuniv, it has a different chemical structure from each of these alternatives.

Direct answer: No FDA-approved conversion table exists for switching between Vyvanse and other ADHD medications. In practice, clinicians typically use a same-day crossover with no mandatory washout, guided by the pharmacokinetic fact stated in the FDA prescribing information that a 30 mg dose of lisdexamfetamine yields roughly 8.9 mg of active d-amphetamine after enzymatic conversion. Everything beyond that base conversion fact, including specific milligram equivalence tables between Vyvanse and Adderall, Concerta, or Focalin, reflects clinical convention and published pharmacokinetic reasoning rather than a labeled equivalence, and doses still require individualized titration under a prescriber's direct supervision.

How the prodrug mechanism shapes a switch

Lisdexamfetamine has no stimulant activity as swallowed. It is L-lysine bonded to d-amphetamine, and the bond must be cleaved by enzymes primarily active in red blood cells before d-amphetamine reaches circulation. This is why plasma d-amphetamine rises gradually over roughly 1 to 2 hours rather than spiking quickly, and why the drug is described as producing a smoother onset and offset curve than immediate-release amphetamine. The rate-limiting step is enzymatic, not related to gut dissolution, which is part of why crushing or dissolving the capsule does not meaningfully speed absorption. This mechanism is described in the current FDA prescribing information for Vyvanse, though the revision date should be reconfirmed at the time of publication since labels are periodically updated.

Because the conversion happens in blood, food delays time to peak concentration by roughly an hour without changing total drug exposure, according to the label. That matters practically during a switch: a patient does not need to standardize meals around Vyvanse dosing to keep the conversion predictable, though a consistent daily routine makes it easier to judge whether a dose change is working.

The clinical implication for switching is straightforward and worth stating plainly: a patient moving from a fast-onset, short-duration stimulant to Vyvanse will feel a different curve on day one, not necessarily a weaker or stronger effect, and that difference in subjective onset is not itself a sign the new dose is wrong.

How much Vyvanse is equivalent to my current stimulant dose?

The only equivalence anchored to primary regulatory evidence is the label's statement that 30 mg lisdexamfetamine yields approximately 8.9 mg of d-amphetamine base. Everything downstream of that, comparing lisdexamfetamine to mixed amphetamine salts, dextroamphetamine, or methylphenidate, is derived by clinicians from that base ratio combined with known amphetamine and methylphenidate potency relationships, not from a head-to-head bioequivalence study. Treat the figures below as a starting point for a prescriber's judgment, not a substitute for it.

Vyvanse-to-amphetamine starting-point estimates (clinician judgment, not an FDA-labeled equivalence):

Two cautions apply to this table. First, methylphenidate and amphetamine act through different mechanisms (dopamine reuptake inhibition versus vesicular monoamine release and reuptake inhibition), so cross-class ratios are looser approximations than same-class ones. Second, individual response varies enough that the correct starting dose for one patient can be one step above or below this table's estimate; the table exists to prevent wildly mismatched starting doses, not to replace a follow-up visit.

Is a same-day switch safe, or do you need a washout?

For switches within the stimulant class (amphetamine to amphetamine, or methylphenidate to amphetamine), the common clinical approach is a direct crossover: take the last dose of the current medication as scheduled, then start the new medication the next scheduled dosing day, with no drug-free washout period required. This is standard practice because both drug classes clear from the body within roughly a day and there is no known pharmacodynamic reason to leave a gap.

Switching to or from a non-stimulant is different and generally should not be done as an abrupt crossover, because non-stimulants like atomoxetine and guanfacine ER take weeks to reach full effect and are not simple substitutes on day one. An overlap-and-taper approach, described below, is the more common pattern.

Switching from an immediate-release amphetamine to Vyvanse

This switch is usually prompted by inconsistent afternoon coverage, the burden of twice-daily dosing, or misuse-risk concerns given lisdexamfetamine's prodrug design, which is generally considered to have lower intranasal or intravenous misuse potential than an active amphetamine salt because the conversion step depends on enzymatic activity rather than the route of administration.

A practical protocol:

1. Total the current daily amphetamine dose (for example, Adderall IR 10 mg twice daily equals 20 mg/day).
2. Use the equivalence table above as a starting estimate for the Vyvanse dose.
3. Stop the immediate-release amphetamine after its last scheduled dose and start Vyvanse the next morning.
4. Schedule follow-up within 1 to 2 weeks and adjust in single-capsule-strength increments (Vyvanse is supplied in 10, 20, 30, 40, 50, 60, and 70 mg capsules), no more than once weekly, based on symptom coverage and side effects.

Switching from methylphenidate (Concerta, Ritalin, Focalin) to Vyvanse

This is a cross-class switch, generally considered when a patient has an inadequate response or intolerable side effects on methylphenidate. Clinical trials have compared lisdexamfetamine against osmotic-release methylphenidate directly, and some have reported greater symptom reduction with lisdexamfetamine on standardized ADHD rating scales; the specific trial, its effect sizes, and any attributed investigator statement should be verified against the primary published paper before being cited to a patient or used as a comparative efficacy claim, since the source material for this article could not be independently confirmed at the level of exact figures or quotations.

A practical protocol:

1. Stop methylphenidate after the last scheduled dose.
2. Estimate an amphetamine-equivalent dose using the roughly 2.5:1 methylphenidate-to-amphetamine convention described above, then match to the nearest Vyvanse strength.
3. Start Vyvanse the next morning and follow up within 1 to 2 weeks.
4. For dexmethylphenidate, use the closer 1.25:1 ratio since it is already the active enantiomer.

Some clinicians deliberately start one capsule strength below the calculated equivalent to reduce overstimulation risk, accepting that the patient may be undertreated for a week or two while the dose is titrated upward. This is a site-judgment tradeoff, not a labeled recommendation, and should be discussed explicitly with the patient.

Switching from Vyvanse to another stimulant

Reasons to switch away from Vyvanse include formulary restrictions, cost, or a preference for a shorter-acting agent with flexible afternoon dosing. Generic lisdexamfetamine became available in the United States in 2023; current formulary status and pricing change over time and should be confirmed with the patient's pharmacy or insurer rather than assumed from this article.

To Adderall XR: both are amphetamine-based extended-release products, so the switch is comparatively direct using the equivalence logic above. The subjective experience can still differ, because Adderall XR uses a bead-based, two-pulse release profile, while lisdexamfetamine's release depends on a single ongoing enzymatic conversion curve, per the FDA label.

To Concerta or another methylphenidate product: this is a cross-class switch. Multiply the estimated d-amphetamine dose by roughly 2.5 to approximate a methylphenidate-equivalent starting dose, then round to the nearest available strength, and titrate from there.

To an immediate-release stimulant: the same conversion logic applies, split across two or three doses per day, with counseling that each dose will cover fewer hours than Vyvanse did.

Should you switch to a non-stimulant instead?

Non-stimulants are generally considered when stimulants cause cardiovascular effects a clinician judges concerning (for example, a resting heart rate increase well above baseline, or blood pressure elevation), or when a patient has an active substance use disorder that makes a stimulant a higher-risk choice. Atomoxetine and the alpha-2 agonists (guanfacine ER, clonidine ER) are the two non-stimulant classes typically used.

Comparative trials have reported that lisdexamfetamine produces larger symptom reductions than atomoxetine on average, but the exact effect sizes attributed to a specific named trial in earlier drafts of this content could not be verified against the primary literature and are not repeated here as precise numbers. What is well established, independent of any single trial, is that atomoxetine and guanfacine ER take weeks rather than hours to reach full effect, which changes how a switch should be sequenced.

A general overlap approach for atomoxetine:

1. Start atomoxetine at a low weight-based dose while the patient continues Vyvanse.
2. After roughly a week, increase atomoxetine toward its target dose as tolerated.
3. Taper Vyvanse gradually rather than stopping it abruptly, coordinated with the atomoxetine titration.
4. Counsel the patient that atomoxetine typically needs several weeks to reach full effect, so a period of reduced symptom control during the transition is expected, not necessarily a sign the plan has failed.

A general overlap approach for guanfacine ER:

1. Start guanfacine ER at a low dose, titrating upward gradually toward the target range.
2. Overlap Vyvanse during the first several weeks of guanfacine titration.
3. Taper and stop Vyvanse once guanfacine reaches a therapeutic dose, watching for hypotension or bradycardia, which are known risks of alpha-2 agonists.

Individual dosing (mg/kg targets, exact titration speed) should be set by the prescriber based on the patient's age, weight, comorbidities, and response, not estimated from a general article.

What actually needs monitoring after any stimulant switch

The clearest gap in most switch protocols is not the dose math, it is the absence of a structured follow-up plan. The weeks immediately after a switch are when treatment failure, side effects, and dropout are most likely, and a scheduled check-in catches problems earlier than waiting for the next routine appointment.

Clinician-discussion and monitoring framework for a Vyvanse switch

Before the switch (shared decision points):

• Confirm the reason for switching (efficacy, side effects, cost, misuse concern, formulary) since the reason shapes the follow-up plan.
• Review cardiovascular history, current heart rate and blood pressure, psychiatric comorbidities, and substance use history.
• Agree on who to contact and how fast if symptoms worsen or new side effects appear (same-day nurse line versus next scheduled visit).
• Clarify that any dose figures discussed are starting-point estimates, not guarantees of equivalence.

Week 1 checkpoint:

• Ask specifically about morning onset and late-afternoon wear-off, not just "is it working."
• Record resting heart rate and blood pressure if feasible.
• Escalate immediately (do not wait for week 2) if the patient reports chest pain, fainting, a resting heart rate increase well above their personal baseline, new or worsening suicidal ideation, or signs of psychosis (this last risk is rare but recognized with stimulants and amphetamines).

Week 2 checkpoint:

• Repeat the symptom check. Adjust the dose by one capsule-strength step if coverage is inadequate, but not more than once per week, to avoid confounding the picture.
• Ask about appetite, sleep onset, and any new anxiety, since these are the most common reasons patients quietly stop a new medication without reporting a problem.

Week 4 checkpoint:

• Use a validated rating scale where available and compare to the pre-switch baseline rather than relying on impression alone.
• Reassess weight, height (in children), and blood pressure trend, not just a single reading.
• Decide explicitly: continue at current dose, titrate further, or consider a different medication class if response remains inadequate after an adequate trial.

Stop-and-reassess conditions at any checkpoint:

• Cardiovascular symptoms (palpitations, chest pain, fainting) warrant same-day contact with the prescriber or urgent care, not waiting for the next scheduled check-in.
• New psychiatric symptoms (mood changes, suicidal thoughts, hallucinations) warrant the same urgency.
• A patient reporting misuse urges, diversion pressure, or using more than prescribed should trigger a direct conversation about the medication plan, not a silent dose increase.

Boundary between label guidance and individualized care:

• The FDA label establishes the approved dose range (20 to 70 mg/day for ADHD; 50 to 70 mg/day for binge eating disorder) and the general pharmacokinetic facts cited above. It does not specify a switching protocol, a conversion table between stimulants, or a monitoring schedule.
• Guideline bodies addressing ADHD in children generally recommend titrating to the dose that achieves symptom control with tolerable side effects, reassessed with input from parents, teachers, or the patient directly, but the specific wording and citation for any such guideline should be verified against the current published version before being quoted to a patient.
• Everything else in this framework, including the exact week-by-week cadence and the specific escalation thresholds, reflects common clinical practice and site judgment rather than a single binding standard, and a prescriber may reasonably adjust it for an individual patient.

Special situations that need extra caution

Binge eating disorder. Vyvanse is the only stimulant with an FDA-approved indication for binge eating disorder, at doses of 50 to 70 mg/day. A patient switching away from Vyvanse for this indication is not switching to an equivalent alternative; no other stimulant carries this approval, and the conversation should address that directly rather than implying a drop-in replacement exists.

CYP2D6 metabolism and atomoxetine. Atomoxetine is extensively metabolized by the CYP2D6 enzyme, and people with reduced CYP2D6 function can reach substantially higher plasma levels than typical metabolizers at the same dose. If a Vyvanse-to-atomoxetine switch is planned and CYP2D6 status is unknown, a conservative starting dose with a longer hold before increasing is a reasonable precaution, and this should be discussed with the prescriber rather than decided unilaterally.

Pregnancy. The FDA label for Vyvanse lists amphetamine exposure as associated with risks including premature delivery and low birth weight based on available human data. Any medication switch during pregnancy or while planning pregnancy should be managed jointly by an obstetric or maternal-fetal medicine clinician and the prescribing clinician, not decided from a general reference article.

Comorbid anxiety. Amphetamine dose changes can transiently worsen anxiety symptoms during the adjustment window. Some clinicians prefer to keep an existing anxiolytic regimen stable through a stimulant switch rather than changing two medications at once, so that a new symptom can be attributed to one change rather than two.

What is established, what is plausible, and what is not established

Established: Lisdexamfetamine is an FDA-approved prodrug that requires enzymatic activation, producing a gradual onset and an extended duration of action compared with immediate-release amphetamine. The FDA-approved dose range is 20 to 70 mg/day for ADHD and 50 to 70 mg/day for binge eating disorder. No FDA-approved conversion table exists between Vyvanse and other stimulants.

Plausible but not tightly quantified in verified primary sources for this article: The commonly used clinical ratios (roughly 30 mg Vyvanse to 10 mg mixed amphetamine salts; roughly 2.5:1 methylphenidate-to-amphetamine) are widely used in practice and consistent with the FDA label's d-amphetamine yield figure, but they are approximations derived by clinicians, not bioequivalence-tested equivalences, and individual response varies.

Not established from the material available for this article: Specific head-to-head effect-size comparisons between lisdexamfetamine and OROS-methylphenidate or atomoxetine, and any direct quotations attributed to trial investigators, could not be verified against the primary literature during this review and have been removed or generalized rather than presented as confirmed figures. A reader who needs exact effect sizes for a clinical or research purpose should pull the original trial publications directly rather than relying on this summary.

References

1. U.S. Food and Drug Administration. Vyvanse (lisdexamfetamine dimesylate) prescribing information. Confirm this reflects the currently in-effect label revision at time of publication.

Additional evidence referenced in earlier versions of this content, including specific head-to-head trial effect sizes and quoted statements attributed to trial investigators, could not be verified against the primary literature during this review. Editorial and medical review should locate and confirm the original publications before any specific effect size, p-value, or quotation is reinstated.